The global injectable drug delivery device market is projected to witness a considerable growth rate by exhibiting a significant CAGR of 9.2%, during the forecast period. Rising incidence and treatment of chronic diseases such as CVD, cancer, diabetes, and other major diseases is one of the major factors augmenting the growth of the global injectable drug delivery devices market. According to the International Diabetes Federation, there are more than 425 million people living with diabetes across the globe. Moreover, in 2018, around 18 million new cases of cancer were registered across the globe, as per World Health Organization (WHO). Additionally, rising awareness towards vaccination is augmenting the demand for injectable drug delivery devices across the globe. Other factors that are raising the growth of the market are technological advancement, innovations and ongoing R&Ds for the introduction of minimally invasive drug delivery devices. 

One of the major factors restraining the growth of the market is unsafe injection practices by the physicians. Diseases including hepatitis B, hepatitis C, and HIV/AIDS can be passed through unsafe injections. The unsafe injection sometimes causes abscesses, septicemia & nerve damage, and hemorrhagic fevers, and malaria. The growing adoption of self-injectable drug delivery devices in emerging economies is an opportunity for market growth. 

Segmental Outlook

The global injectable drug delivery device market is segmented on the basis of device type, application, and end-user. Based on device type, the market is bifurcated into conventional drug delivery devices and self-injectable drug delivery devices. Self-injectable delivery devices are further divided into prefilled syringes, injectable pens, auto-injectors, needle-free injectors, and others. Based on application, the market is divided into CVD, diabetes, oncology, general medication, vaccination, and others. Based on end-user, the market is segmented into hospitals, ambulatory centers, clinics, and homecare. Among these end-users, the hospitals are projected to have a significant share in the market; whereas, home care is expected to show a considerable growth rate in the market due to increasing homecare-based injectables, such as insulin patch pumps. 

Self-Injectable Drug Delivery Devices are projected to exhibit significant growth in the market 

Self-injectable syringes are expected to grow with a significant growth rate during the forecast period due to the growing adoption of prefilled syringes across the globe. Companies such as Eli Lilly are providing cancer treatment drugs, including Taltz (ixekizumab) and Emgality (galcanezumab-gnlm) in injectables pens and prefilled injectable syringes, which are quite expensive compared to conventional injectable delivery devices. Adoption of prefilled is increasing due to the ease of use, has lesser steps to inject which reduces the chances of unsafe injection, contamination, and needlestick injuries. Moreover, it has less risk of valuable API and a lesser risk of dosing errors. 

Global Injectable Drug Delivery Device Market Share by Application, 2018 (%)

Image

Regional Outlook 

Geographically, the global injectable drug delivery device market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to contribute a significant share in the global injectable drug delivery device market, owing to the substantial presence of self-injecting drug delivery device market in the region. Patent for the treatment of fatal diseases through self-injecting drugs is generating significant revenue for the market in the region. Moreover, the high awareness toward diseases and its vaccination along with availability of reimbursement policies are some of the major factors driving the North American market. Europe is also expected to hold a significant market due to the similar reason of North America including patented drugs, awareness toward diseases and vaccination, and increasing adoption of self-injecting drug devices. 

Global Injectable Drug Delivery Device Market Growth, by Region 2019-2025

Image

Asia-Pacific is expected to witness significant growth in the global market 

By volume, Asia-Pacific is projected to contribute a substantial share in the global injectable drug delivery device market. However, the penetration of self-injecting drug delivery devices in the emerging economies is still low, which is expected to grow with a significant growth rate during the forecast period. Countries such as China, India, Indonesia will hold a significant market due to the large population base. Rising awareness towards vaccination, increasing health insurance penetration, and rising incidences of chronic diseases are expected to provide lucrative growth to the market. High disposable income and a large proportion of the geriatric population in Japan are creating a demand for healthcare facilities and are expected to grow at a modest rate. 

Market Players Outlook

The major players contributing to the growth of the global injectable drug delivery device market include Cardinal Health, Inc., Gerresheimer AG, Schott AG, Becton, Dickinson and Co., Wilhelm Haselmeier GmbH & Co. KG, and Pfizer Inc. The market players are significantly contributing to the market growth by the adoption of various strategies, including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market. 

Recent Activities

• In May 2018, Haselmeier and Common Sensing partnered in order to develop smart connected monitoring and support solution for users of injectable medicines. Both the companies are working to develop smart disposable injector pen platform, Gocap, which is expected to be available in 2019. 
• In July 2017, Baxter International, Inc. completed the acquisition of Claris Injectables Ltd., a generic injectables pharmaceutical company. The aim of the acquisition is to broaden its product portfolio in generic injectable medicines. The company got access to Claris Injectables product portfolio and pipeline and three manufacturing plants. The transaction valued near to $625 million.
• In April 2017, Cardinal Health, Inc., acquired Medtronic’s medical supply business for $6.1 billion. The acquisition will increase the company’s product portfolio for operation rooms, long-term care facilities, and in-home healthcare. Medtronic medical supplies business brands include Curity, Kendall, Dover, Argyle, and Kangaroo.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global injectable drug delivery device market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.